These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 29776413)

  • 21. Naringin enhances endothelial progenitor cell (EPC) proliferation and tube formation capacity through the CXCL12/CXCR4/PI3K/Akt signaling pathway.
    Zhao Z; Ma X; Ma J; Sun X; Li F; Lv J
    Chem Biol Interact; 2018 Apr; 286():45-51. PubMed ID: 29510123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of C-X-C Chemokine Receptor Type 4 (CXCR4) in Cell Adherence and Spheroid Formation of Human Ewing's Sarcoma Cells under Simulated Microgravity.
    Romswinkel A; Infanger M; Dietz C; Strube F; Kraus A
    Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31810195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential regulation of CXCR4-mediated T-cell chemotaxis and mitogen-activated protein kinase activation by the membrane tyrosine phosphatase, CD45.
    Fernandis AZ; Cherla RP; Ganju RK
    J Biol Chem; 2003 Mar; 278(11):9536-43. PubMed ID: 12519755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.
    Teng F; Tian WY; Wang YM; Zhang YF; Guo F; Zhao J; Gao C; Xue FX
    J Hematol Oncol; 2016 Feb; 9():8. PubMed ID: 26851944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Lentiviral CXCR4 overexpression and knockdown model in colorectal cancer cell lines reveals plerixafor-dependent suppression of SDF-1α-induced migration and invasion.
    Heckmann D; Laufs S; Maier P; Zucknick M; Giordano FA; Veldwijk MR; Eckstein V; Wenz F; Zeller WJ; Fruehauf S; Allgayer H
    Onkologie; 2011; 34(10):502-8. PubMed ID: 21985848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Curcumin modulates SDF-1alpha/CXCR4-induced migration of human retinal endothelial cells (HRECs).
    Sameermahmood Z; Balasubramanyam M; Saravanan T; Rema M
    Invest Ophthalmol Vis Sci; 2008 Aug; 49(8):3305-11. PubMed ID: 18660423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The
    Pansy K; Feichtinger J; Ehall B; Uhl B; Sedej M; Roula D; Pursche B; Wolf A; Zoidl M; Steinbauer E; Gruber V; Greinix HT; Prochazka KT; Thallinger GG; Heinemann A; Beham-Schmid C; Neumeister P; Wrodnigg TM; Fechter K; Deutsch AJ
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
    Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
    PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PTEN loss activates a functional AKT/CXCR4 signaling axis to potentiate tumor growth and lung metastasis in human osteosarcoma cells.
    Xi Y; Qi Z; Ma J; Chen Y
    Clin Exp Metastasis; 2020 Feb; 37(1):173-185. PubMed ID: 31571016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4.
    Hersi HM; Raulf N; Gaken J; Folarin N; Tavassoli M
    Mol Oncol; 2018 Dec; 12(12):2023-2041. PubMed ID: 29959873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway.
    Liang Z; Brooks J; Willard M; Liang K; Yoon Y; Kang S; Shim H
    Biochem Biophys Res Commun; 2007 Aug; 359(3):716-22. PubMed ID: 17559806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional potentials of human hematopoietic progenitor cells are maintained by mesenchymal stromal cells and not impaired by plerixafor.
    Ludwig A; Saffrich R; Eckstein V; Bruckner T; Wagner W; Ho AD; Wuchter P
    Cytotherapy; 2014 Jan; 16(1):111-21. PubMed ID: 24119647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Some research progress of CXCR4 antagonist AMD3100].
    Chang CK; Zhang X; Zhao YS; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):831-4. PubMed ID: 21729582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.
    Wu M; Chen Q; Li D; Li X; Li X; Huang C; Tang Y; Zhou Y; Wang D; Tang K; Cao L; Shen S; Li G
    J Cell Biochem; 2008 Jan; 103(1):245-55. PubMed ID: 17549698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
    Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
    Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma.
    Yu L; Deng Y; Wang X; Santos C; Davis IJ; Earp HS; Liu P
    Nat Commun; 2024 Jun; 15(1):5292. PubMed ID: 38906855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis.
    Badr G; Lefevre EA; Mohany M
    PLoS One; 2011; 6(9):e23741. PubMed ID: 21912642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
    Kajiyama H; Shibata K; Terauchi M; Ino K; Nawa A; Kikkawa F
    Int J Cancer; 2008 Jan; 122(1):91-9. PubMed ID: 17893878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
    De Clercq E
    Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.
    Fricker SP; Anastassov V; Cox J; Darkes MC; Grujic O; Idzan SR; Labrecque J; Lau G; Mosi RM; Nelson KL; Qin L; Santucci Z; Wong RS
    Biochem Pharmacol; 2006 Aug; 72(5):588-96. PubMed ID: 16815309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.